Theranos promised to transform medicine with fast, inexpensive tests using very small blood samples. The company became a symbol of Silicon Valley ambition before reporting and investigations exposed serious problems with its technology and claims.
Founder Elizabeth Holmes was convicted of fraud-related offenses involving investors and was sentenced to prison. Theranos never perfected the blood-testing system it promoted.
The story did not end at the criminal sentence. In April 2025, a U.S. Department of Health and Human Services administrative law judge issued a decision concerning Holmes and an exclusion action brought by the HHS Office of Inspector General.
The written decision reviews representations made to investors, the failure of the technology to deliver as promised, and the criminal case. It is a reminder that the consequences of a high-profile scandal can travel through several different legal and regulatory processes.
That does not mean every issue associated with Theranos is resolved, or that a single administrative ruling answers every question from patients and investors. It means that after the documentary credits and courtroom headlines, formal proceedings continued.
The vanished headline has an enduring answer: the promised technology failed, the founder was convicted, and the public record continued to grow.
THE PAPER TRAIL
Sources for the reporting above. Follow the documents, not just our interpretation.
This article reflects sources reviewed for the inaugural edition. Updates and corrections should be dated and supported by new evidence.